{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:51Z","timestamp":1794893631656,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant chemoradiotherapy (CRT) constitutes a standard treatment for locally advanced rectal cancer (RC), frequently followed by radical surgical resection. Yet, therapeutic responses vary widely, and intrinsic radioresistance remains a major barrier to cure. To uncover actionable determinants of CRT response, we established a panel of patient-derived colorectal cancer cell lines (PDCLs) followed by integrated phenotypic and functional characterization. We identified metabolic reprogramming as a hallmark of radioresistance and, through orthogonal validation experiments, confirmed elevated glycolytic and mitochondrial ATP production in (chemo)irradiation-resistant PDCLs. The causative relationship of this association and its potential for therapeutic intervention was shown by subsequent drug screening, showing resistance to most of the applied drugs and revealing a critical dependency on the monocarboxylate transporter (MCT1) and the glucose transporter 1 (GLUT1). Metabolism-targeting compounds re-sensitized resistant PDCLs to irradiation; especially inhibition of GLUT1 exhibits a robust radiosensitizing activity across models. Concordantly, GLUT1 expression correlated with poor response to neoadjuvant CRT in our own RC patient cohort and various publicly available patient datasets. Collectively, our study defines metabolic dependency as a key driver of CRT resistance in RC, and reveals glycolysis- and lactate-transport-associated pathway activities as targetable vulnerabilities. These findings provide a mechanistic basis for patient stratification and support the development of metabolism-directed strategies to overcome (chemo)radioresistance in RC.<\/jats:p>","DOI":"10.1186\/s13046-026-03755-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:45:17Z","timestamp":1782200717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Maximilian","family":"Hellkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gertken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Buchloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius-Leonard","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas Ben","family":"Kowitzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Gaspardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00fcffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linnebacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Str\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Ellenrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Gaedcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wienands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Spitzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Grade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"3755_CR1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41575-024-00900-9","volume":"21","author":"Y Kagawa","year":"2024","unstructured":"Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21:444\u201355. https:\/\/doi.org\/10.1038\/s41575-024-00900-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3755_CR2","doi-asserted-by":"publisher","unstructured":"Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. Longo DL, editor. N Engl J Med. 2022;386:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMra2200869.","DOI":"10.1056\/NEJMra2200869"},{"key":"3755_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3238\/arztebl.m2022.0254","volume":"119","author":"M Ghadimi","year":"2022","unstructured":"Ghadimi M, R\u00f6del C, Hofheinz R, Flebbe H, Grade M. Multimodal Treatment of Rectal Cancer. Dtsch Arztebl Int. 2022;119:570\u201380. https:\/\/doi.org\/10.3238\/arztebl.m2022.0254.","journal-title":"Dtsch Arztebl Int"},{"key":"3755_CR4","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO.24.01160","volume":"42","author":"AJ Scott","year":"2024","unstructured":"Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024;42:3355\u201375. https:\/\/doi.org\/10.1200\/JCO.24.01160.","journal-title":"J Clin Oncol"},{"key":"3755_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/OP.20.00885","volume":"17","author":"BW Deschner","year":"2021","unstructured":"Deschner BW, VanderWalde NA, Grothey A, Shibata D. Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. JCO Oncol Pract. 2021;17:383\u2013402. https:\/\/doi.org\/10.1200\/OP.20.00885.","journal-title":"JCO Oncol Pract"},{"key":"3755_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41575-020-0275-y","volume":"17","author":"DS Keller","year":"2020","unstructured":"Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17:414\u201329. https:\/\/doi.org\/10.1038\/s41575-020-0275-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3755_CR7","doi-asserted-by":"publisher","first-page":"e2350903","DOI":"10.1001\/jamanetworkopen.2023.50903","volume":"7","author":"HM Thompson","year":"2024","unstructured":"Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Verheij FS, et al. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2350903. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50903.","journal-title":"JAMA Netw Open"},{"key":"3755_CR8","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40:2546\u201356. https:\/\/doi.org\/10.1200\/JCO.22.00032.","journal-title":"J Clin Oncol"},{"key":"3755_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, Lin ST, Qin L-X, Buckley JT, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42:500\u20136. https:\/\/doi.org\/10.1200\/JCO.23.01208.","journal-title":"J Clin Oncol"},{"key":"3755_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.23.01369","volume":"42","author":"A Loria","year":"2024","unstructured":"Loria A, Ramsdale EE, Aquina CT, Cupertino P, Mohile SG, Fleming FJ. From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer. J Clin Oncol. 2024;42:876\u201380. https:\/\/doi.org\/10.1200\/JCO.23.01369.","journal-title":"J Clin Oncol"},{"key":"3755_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/JCO.22.01812","volume":"41","author":"WA Hall","year":"2023","unstructured":"Hall WA, Smith JJ. Achieving a Cure Without Total Mesorectal Excision in Rectal Adenocarcinoma. J Clin Oncol. 2023;41:173\u201380. https:\/\/doi.org\/10.1200\/JCO.22.01812.","journal-title":"J Clin Oncol"},{"key":"3755_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41571-021-00538-5","volume":"18","author":"E Fokas","year":"2021","unstructured":"Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18:805\u201316. https:\/\/doi.org\/10.1038\/s41571-021-00538-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"3755_CR13","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.3390\/cancers16213673","volume":"16","author":"M Diefenhardt","year":"2024","unstructured":"Diefenhardt M, Martin D, Fleischmann M, Hofheinz R-D, Ghadimi M, R\u00f6del C, et al. Tumor Response and Its Impact on Treatment Failure in Rectal Cancer: Does Intensity of Neoadjuvant Treatment Matter? Cancers (Basel). 2024;16:3673. https:\/\/doi.org\/10.3390\/cancers16213673.","journal-title":"Cancers (Basel)"},{"key":"3755_CR14","doi-asserted-by":"publisher","first-page":"e2340256","DOI":"10.1001\/jamanetworkopen.2023.40256","volume":"6","author":"M Diefenhardt","year":"2023","unstructured":"Diefenhardt M, Martin D, Fleischmann M, Hofheinz R-D, Ghadimi M, R\u00f6del C, et al. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Netw Open. 2023;6:e2340256. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.40256.","journal-title":"JAMA Netw Open"},{"key":"3755_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","volume":"17","author":"AM Buckley","year":"2020","unstructured":"Buckley AM, Lynam-Lennon N, O\u2019Neill H, O\u2019Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 2020;17:298\u2013313. https:\/\/doi.org\/10.1038\/s41575-019-0247-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3755_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409\u201325. https:\/\/doi.org\/10.1038\/nrc3958.","journal-title":"Nat Rev Cancer"},{"key":"3755_CR17","doi-asserted-by":"publisher","first-page":"a026781","DOI":"10.1101\/cshperspect.a026781","volume":"7","author":"E Hirata","year":"2017","unstructured":"Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med. 2017;7:a026781. https:\/\/doi.org\/10.1101\/cshperspect.a026781.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3755_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12029-025-01324-7","volume":"56","author":"A Micu","year":"2025","unstructured":"Micu A, Diaconescu A, Minciuna C-E, Manuc T, Dima SO, Droc G, et al. Overcoming the Challenge: A Comprehensive Review of Neoadjuvant Treatment Resistance in Rectal Cancer. J Gastrointest Cancer. 2025;56:205. https:\/\/doi.org\/10.1007\/s12029-025-01324-7.","journal-title":"J Gastrointest Cancer"},{"key":"3755_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ijc.28429","volume":"134","author":"M Spitzner","year":"2014","unstructured":"Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer. 2014;134:997\u20131007. https:\/\/doi.org\/10.1002\/ijc.28429.","journal-title":"Int J Cancer"},{"key":"3755_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/1541-7786.MCR-17-0205","volume":"15","author":"G Emons","year":"2017","unstructured":"Emons G, Spitzner M, Reineke S, M\u00f6ller J, Auslander N, Kramer F, et al. Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt\/\u03b2-catenin Signaling. Mol Cancer Res. 2017;15:1481\u201390. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0205.","journal-title":"Mol Cancer Res"},{"key":"3755_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/cancers13030455","volume":"13","author":"K Koerdel","year":"2021","unstructured":"Koerdel K, Spitzner M, Meyer T, Engels N, Krause F, Gaedcke J, et al. NOTCH Activation via gp130\/STAT3 Signaling Confers Resistance to Chemoradiotherapy. Cancers (Basel). 2021;13:455. https:\/\/doi.org\/10.3390\/cancers13030455.","journal-title":"Cancers (Basel)"},{"key":"3755_CR22","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/cancers11101520","volume":"11","author":"CS Mullins","year":"2019","unstructured":"Mullins CS, Micheel B, Matschos S, Leuchter M, B\u00fcrtin F, Krohn M, et al. Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research. Cancers (Basel). 2019;11:1520. https:\/\/doi.org\/10.3390\/cancers11101520.","journal-title":"Cancers (Basel)"},{"key":"3755_CR23","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ueg2.70086","volume":"13","author":"J Buchloh","year":"2025","unstructured":"Buchloh J, Spitzner M, Zimmermann H, Fang X, Tapia Contreras C, Schneider C, et al. Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer. United Eur Gastroenterol J. 2025;13:1690\u2013702. https:\/\/doi.org\/10.1002\/ueg2.70086.","journal-title":"United Eur Gastroenterol J"},{"key":"3755_CR24","doi-asserted-by":"publisher","first-page":"e8428","DOI":"10.15252\/emmm.201708428","volume":"10","author":"H Bohnenberger","year":"2018","unstructured":"Bohnenberger H, Kaderali L, Str\u00f6bel P, Yepes D, Plessmann U, Dharia NV, et al. Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis. EMBO Mol Med. 2018;10:e8428. https:\/\/doi.org\/10.15252\/emmm.201708428.","journal-title":"EMBO Mol Med"},{"key":"3755_CR25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NAP Franken","year":"2006","unstructured":"Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315\u20139. https:\/\/doi.org\/10.1038\/nprot.2006.339.","journal-title":"Nat Protoc"},{"key":"3755_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/1878-0261.13725","volume":"19","author":"C Tapia Contreras","year":"2025","unstructured":"Tapia Contreras C, Falke JD, Seifert D-M, Schneider C, Krau\u00df L, Fang X, et al. KRASG 12\u00a0C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Mol Oncol. 2025;19:295\u2013310. https:\/\/doi.org\/10.1002\/1878-0261.13725.","journal-title":"Mol Oncol"},{"key":"3755_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1186\/s12885-017-3689-3","volume":"17","author":"NA Clark","year":"2017","unstructured":"Clark NA, Hafner M, Kouril M, Williams EH, Muhlich JL, Pilarczyk M, et al. GRcalculator: an online tool for calculating and mining dose-response data. BMC Cancer. 2017;17:698. https:\/\/doi.org\/10.1186\/s12885-017-3689-3.","journal-title":"BMC Cancer"},{"key":"3755_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93\u2013141.","journal-title":"Pharmacol Rev"},{"key":"3755_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. San Diego Calif. 2001;25:402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"San Diego Calif"},{"key":"3755_CR30","unstructured":"FastQC. A quality control tool for high throughput sequence data. [Internet]. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"3755_CR31","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, K\u00e4ller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btw354.","journal-title":"Bioinformatics"},{"key":"3755_CR32","unstructured":"The R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. [Internet]. 2025. https:\/\/www.R-project.org\/."},{"key":"3755_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"key":"3755_CR34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330. https:\/\/doi.org\/10.1093\/bioinformatics\/btt656.","journal-title":"Bioinformatics"},{"key":"3755_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"3755_CR36","unstructured":"Galaxy Europe [Internet]. https:\/\/usegalaxy.eu."},{"key":"3755_CR37","unstructured":"GenePattern. GSEA [Internet]. https:\/\/www.gsea-msigdb.org\/gsea\/index.jsp."},{"key":"3755_CR38","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3755_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"3755_CR40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41416-022-01842-2","volume":"127","author":"G Emons","year":"2022","unstructured":"Emons G, Auslander N, Jo P, Kitz J, Azizian A, Hu Y, et al. Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. Br J Cancer. 2022;127:766\u201375. https:\/\/doi.org\/10.1038\/s41416-022-01842-2.","journal-title":"Br J Cancer"},{"key":"3755_CR41","unstructured":"cBioPortal [Internet]. https:\/\/www.cbioportal.org."},{"key":"3755_CR42","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83:3861\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0816.","journal-title":"Cancer Res"},{"key":"3755_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"key":"3755_CR44","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"key":"3755_CR45","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","volume":"28","author":"WK Chatila","year":"2022","unstructured":"Chatila WK, Kim JK, Walch H, Marco MR, Chen C-T, Wu F, et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med. 2022;28:1646\u201355. https:\/\/doi.org\/10.1038\/s41591-022-01930-z.","journal-title":"Nat Med"},{"key":"3755_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330\u20137. https:\/\/doi.org\/10.1038\/nature11252.","journal-title":"Nature"},{"key":"3755_CR47","unstructured":"GeneTrail [Internet]. https:\/\/genetrail.bioinf.uni-sb.de\/."},{"key":"3755_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19\u201323. https:\/\/doi.org\/10.1007\/s003840050072.","journal-title":"Int J Colorectal Dis"},{"key":"3755_CR49","unstructured":"Agilent Seahorse. Analystics [Internet]. https:\/\/www.seahorseanalytics.agilent.com."},{"key":"3755_CR50","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.3390\/cancers13235882","volume":"13","author":"S Matschos","year":"2021","unstructured":"Matschos S, B\u00fcrtin F, Kdimati S, Radefeldt M, Krake S, Prall F, et al. The HROC-Xenobank-A High Quality Assured PDX Biobank of >\u2009100 Individual Colorectal Cancer Models. Cancers (Basel). 2021;13:5882. https:\/\/doi.org\/10.3390\/cancers13235882.","journal-title":"Cancers (Basel)"},{"key":"3755_CR51","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ijrobp.2010.06.023","volume":"78","author":"M Spitzner","year":"2010","unstructured":"Spitzner M, Emons G, Kramer F, Gaedcke J, Rave-Fr\u00e4nk M, Scharf J-G, et al. A Gene Expression Signature for Chemoradiosensitivity of Colorectal Cancer Cells. Int J Radiation Oncology*Biology*Physics. 2010;78:1184\u201392. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.023.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"3755_CR52","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.3390\/cancers14153658","volume":"14","author":"M Diefenhardt","year":"2022","unstructured":"Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, et al. Total Neoadjuvant Therapy for Rectal Cancer in the CAO\/ARO\/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. Cancers (Basel). 2022;14:3658. https:\/\/doi.org\/10.3390\/cancers14153658.","journal-title":"Cancers (Basel)"},{"key":"3755_CR53","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.19.00308","volume":"37","author":"E Fokas","year":"2019","unstructured":"Fokas E, Allg\u00e4uer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO\/ARO\/AIO-12. J Clin Oncol. 2019;37:3212\u201322. https:\/\/doi.org\/10.1200\/JCO.19.00308.","journal-title":"J Clin Oncol"},{"key":"3755_CR54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","volume":"13","author":"C R\u00f6del","year":"2012","unstructured":"R\u00f6del C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(12)70187-0.","journal-title":"Lancet Oncol"},{"key":"3755_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6.","journal-title":"Lancet Oncol"},{"key":"3755_CR56","doi-asserted-by":"publisher","unstructured":"Fokas E, Str\u00f6bel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, et al. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. J Natl Cancer Inst. 2017;109. https:\/\/doi.org\/10.1093\/jnci\/djx095.","DOI":"10.1093\/jnci\/djx095"},{"key":"3755_CR57","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11306-025-02319-y","volume":"21","author":"A Kler","year":"2025","unstructured":"Kler A, Fok M, Grundy GJ, Sciacovelli M, Dunn WB, Vimalachandran D. A systematic review of omics discovery studies to identify pertinent metabolic pathways for locally advanced rectal cancer in response to neoadjuvant chemoradiotherapy. Metabolomics. 2025;21:124. https:\/\/doi.org\/10.1007\/s11306-025-02319-y.","journal-title":"Metabolomics"},{"key":"3755_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00384-012-1542-3","volume":"28","author":"BY Shim","year":"2013","unstructured":"Shim BY, Jung J-H, Lee K-M, Kim H-J, Hong SH, Kim SH, et al. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis. 2013;28:375\u201383. https:\/\/doi.org\/10.1007\/s00384-012-1542-3.","journal-title":"Int J Colorectal Dis"},{"key":"3755_CR59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22:96. https:\/\/doi.org\/10.1186\/s12943-023-01801-2.","journal-title":"Mol Cancer"},{"key":"3755_CR60","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13046-019-1214-z","volume":"38","author":"J Lin","year":"2019","unstructured":"Lin J, Xia L, Liang J, Han Y, Wang H, Oyang L, et al. The roles of glucose metabolic reprogramming in chemo- and radio-resistance. J Exp Clin Cancer Res. 2019;38:218. https:\/\/doi.org\/10.1186\/s13046-019-1214-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"3755_CR61","doi-asserted-by":"publisher","first-page":"e70358","DOI":"10.1002\/mco2.70358","volume":"2025","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Yan W, Tong L, Yang J, Ge S, Fan J, et al. Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance. MedComm. 2020;2025(6):e70358. https:\/\/doi.org\/10.1002\/mco2.70358.","journal-title":"MedComm"},{"key":"3755_CR62","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12885-025-14141-9","volume":"25","author":"M Hayashi","year":"2025","unstructured":"Hayashi M, Nakamura K, Harada S, Tanaka M, Kobayashi A, Saito H, et al. GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells. BMC Cancer. 2025;25:716. https:\/\/doi.org\/10.1186\/s12885-025-14141-9.","journal-title":"BMC Cancer"},{"key":"3755_CR63","doi-asserted-by":"publisher","first-page":"101076","DOI":"10.1016\/j.neo.2024.101076","volume":"58","author":"M Cordani","year":"2024","unstructured":"Cordani M, Michetti F, Zarrabi A, Zarepour A, Rumio C, Strippoli R, et al. The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities. Neoplasia. 2024;58:101076. https:\/\/doi.org\/10.1016\/j.neo.2024.101076.","journal-title":"Neoplasia"},{"key":"3755_CR64","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, et al. A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res. 2023;29:1429\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2263.","journal-title":"Clin Cancer Res"},{"key":"3755_CR65","doi-asserted-by":"publisher","first-page":"TPS494","DOI":"10.1200\/jco.2015.33.3_suppl.tps494","volume":"33","author":"RA Redman","year":"2015","unstructured":"Redman RA, Pohlmann PR, Kurman MR, Tapolsky G, Chesney J. A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. JCO. 2015;33:TPS494\u2013494. https:\/\/doi.org\/10.1200\/jco.2015.33.3_suppl.tps494.","journal-title":"JCO"},{"key":"3755_CR66","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/cancers13051011","volume":"13","author":"T De Oliveira","year":"2021","unstructured":"De Oliveira T, Goldhardt T, Edelmann M, Rogge T, Rauch K, Kyuchukov ND, et al. Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo. Cancers (Basel). 2021;13:1011. https:\/\/doi.org\/10.3390\/cancers13051011.","journal-title":"Cancers (Basel)"},{"key":"3755_CR67","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/2767-9764.CRC-24-0077","volume":"4","author":"M Edelmann","year":"2024","unstructured":"Edelmann M, Fan S, De Oliveira T, Goldhardt T, Sartorius D, Midelashvili T, et al. Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy. Cancer Res Commun. 2024;4:2008\u201324. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0077.","journal-title":"Cancer Res Commun"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03755-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03755-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03755-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:32:31Z","timestamp":1782279151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03755-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3755"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03755-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (application number 9\/8\/08). Written informed consent for research was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors reviewed and approved the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"143"}}